The 83rd ADA 2023 Scientific Sessions will be taking place on June 23 – 26th in San Diego, California this year.
Cutting-edge research, treatment recommendations, and medical advancements for diabetes treatment will be revealed at this conference. Leading scientists, health industry leaders, and physicians will attend to gain insights from their peers.
Among the upcoming presentations is Orange Biomed. Our team will be hosting a poster presentation at the diabetes conference in 954-P within the category 13-B New Technology—Glucose Monitoring and Sensing.
On Saturday from 11:30 AM – 12:30 PM, company leadership will be hosting a Q&A to discuss our cutting-edge diabetes research and new methodology with attendees.
Read more about our upcoming presentation below.
Presentation Sneak Peak – Revolutionary New Method of A1c Testing
Orange Biomed has developed the world’s first glycated hemoglobin analyzer through single-cell analysis of red blood cells, OBM rapid A1c.
The new method leverages microfluidic technology the size of red blood cells, enabling highly-accurate results from one drop of blood.
Our healthcare innovation offers several advantages over existing methods,
- Hospitals can achieve a similar level of accuracy at 1/500th the cost (anticipated) of HPLC equipment.
- Requires 100x less blood than other A1c tests on the market, promoting safety and simplicity of blood draw.
- Measurement is unaffected by hemoglobin variant interference, guaranteeing true accuracy for all patient populations.
Orange Biomed aims to provide better diabetes care and diagnostic tools to patients and providers to help reduce the global diabetes burden. We are currently seeking U.S.-based research partners with the goal of obtaining FDA clearance by early 2024.
Reach out to us if you are interested in learning more, or would like to schedule a meeting around the ADA conference.
Check out our MIT Technology Review interview to learn more about Orange Biomed’s innovative diabetes technology.
Sources:
